DCC-3014, Vimseltinib (Deciphera) is the name of a medication currently in trial for TGCT.
It is a Phase 2/3 study, meaning the side effects are being evaluated as well as the effectiveness of the drug. The Phase 3 trial is known as MOTION.
Preliminary data shows it has a tolerability profile and is effective at shrinking TGCT in 50% of patients and reducing disease-related symptoms. Some common side effects identified in 32 patients in the Phase 1 and 36 patients in the Phase 2 include increased creatine phosphokinase (63% in Phase 1 and 53% in Phase 2), facial swelling (53% in Phase 1 and 22% in Phase 2), fatigue (47% in Phase 1 and 17% in Phase 2), increases in liver enzymes (44 and 33%), muscle aches (28% in the Phase 1 and 14% in the Phase 2), itching (25% in Phase 1 and 8% in Phase 2), among others (data).
MOTION is currently recruiting at 18 different global clinical locations. Vimseltinib or a sugar drug (placebo) is given twice weekly for 24 weeks. Following 24 weeks, Vimseltinib is given to all participants. At any time, patients given the sugar pill can cross over into the Vimseltinib group. The objective of this trial is to review tumor shrinkage at 25 weeks, range of motion, and patient reported pain, stiffness, and function.